Investigational drug · Phase 2
PF-08049820
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Atopic Dermatitis, Eczema, Atopic.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
6
Any phase or sponsor naming "PF-08049820"
First trial start
2025
Nov 20, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PF-08049820", any sponsor or status.
Conditions studied
As listed on its trial records.
- Atopic Dermatitis
- Eczema, Atopic
Approved drugs for the same conditions: Atopic dermatitis (eczema) · Immunology and inflammation · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "PF-08049820" as an intervention, largest first.
- A Study to Learn About Study Medicine Called PF-08049820 in People With EczemaPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07216027 · 165 participants (planned) · Start Nov 20, 2025 · Primary completion Feb 2, 2028
Drug: PF-08049820; Placebo · For: Atopic Dermatitis; Eczema, Atopic
Sites: Phoenix, Arizona; Scottsdale, Arizona; Huntington Beach, California · 52 sites in all
PfizerPfizer (PFE)
NCT06686797 · 71 participants · Start Nov 27, 2024 · Primary completion Feb 23, 2026
Drug: PF-08049820; Placebo · For: Healthy
Sites: New Haven, Connecticut
PfizerPfizer (PFE)
NCT07597928 · 24 participants · Start May 13, 2026 · Primary completion Aug 7, 2026
Drug: PF-08049820; Rabeprazole · For: Healthy Adults; Healthy
Sites: New Haven, Connecticut
PfizerPfizer (PFE)
NCT07284173 · 18 participants · Start Nov 3, 2025 · Primary completion Dec 18, 2025
Drug: PF-08049820; Rabeprazole · For: Healthy Adults
Sites: Beijing, China · 2 sites in all
PfizerPfizer (PFE)
NCT07190430 · 16 participants · Start Oct 3, 2025 · Primary completion Dec 15, 2025
Drug: PF-08049820; Midazolam and 2 more · For: Atopic Dermatitis
Sites: New Haven, Connecticut
PfizerPfizer (PFE)
NCT07172321 · 12 participants · Start Sep 5, 2025 · Primary completion Oct 4, 2025
Drug: PF-08049820 MR1; PF-08049820 MR2 and 1 more · For: Atopic Dermatitis
Sites: New Haven, Connecticut
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Atopic Dermatitis
- AfimkibartRO7790121, RVT-3101Phase 312 trials
Roche (Genentech) · Moderately to Severely Active Ulcerative Colitis, Moderately to Severely Active Crohns Disease, Atopic Dermatitis
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- LutikizumabABT-981Phase 38 trials
AbbVie · Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis
- PF-07275315tilrekimigPhase 38 trials
Pfizer · Atopic Dermatitis, Asthma, Moderate to Severe Chronic Obstructive Pulmonary Disease
- barzolvolimabCDX-0159Phase 37 trials
Celldex Therapeutics · Chronic Spontaneous Urticaria, Chronic Inducible Urticaria, Cold Urticaria
- MG-K10Humanized Monoclonal AntibodyPhase 36 trials
Shanghai Mabgeek Biotech.Co.Ltd · Dermatitis, Atopic, Chronic Urticaria, Idiopathic, Atopic Dermatitis
- CM310Phase 35 trials
Keymed Biosciences Co.Ltd · Atopic Dermatitis, Moderate to Severe Asthma, Chronic Obstructive Pulmonary Disease
- VC005Phase 35 trials
Jiangsu vcare pharmaceutical technology co., LTD · Non-segmental Vitiligo, Non-Segmental Vitiligo, Atopic Dermatitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Pfizer.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.